AlectorALEC
ALEC
About: Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Employees: 238
0
Funds holding %
of 7,202 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,286% more call options, than puts
Call options by funds: $402K | Put options by funds: $29K
26% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 34
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
3.24% less ownership
Funds ownership: 74.9% [Q4 2024] → 71.66% (-3.24%) [Q1 2025]
7% less funds holding
Funds holding: 149 [Q4 2024] → 138 (-11) [Q1 2025]
22% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 27
37% less capital invested
Capital invested by funds: $139M [Q4 2024] → $87.8M (-$50.8M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1.50
9%
upside
Avg. target
$5.75
317%
upside
High target
$10
625%
upside
2 analyst ratings
1 positive
50%
0 neutral
0%
1 negative
50%
HC Wainwright & Co. Andrew Fein | 625%upside $10 | Buy Maintained | 9 May 2025 |
Morgan Stanley Sean Laaman | 9%upside $1.50 | Underweight Assumed | 7 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Alector Reports First Quarter 2025 Financial Results and Provides Business Update
Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disease Continuing to pursue Alector Brain Carrier programs, including the company's anti-amyloid beta antibody and its GCase enzyme replacement therapy Extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today reported first quarter 2025 financial results and recent portfolio and business updates.
Neutral
GlobeNewsWire
2 weeks ago
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 13, 2025, at 2:20 p.m.
Neutral
GlobeNewsWire
1 month ago
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease
--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD).
Neutral
GlobeNewsWire
1 month ago
Alector Provides Executive Leadership Update
--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role--
Neutral
Seeking Alpha
2 months ago
Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript
Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal - Co-Founder and Chief Executive Officer Gary Romano - Chief Medical Officer Sara Kenkare-Mitra - President and Head, Research and Development Marc Grasso - Chief Financial Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Alec Stranahan - Bank of America Securities Thomas Shrader - BTIG Yaron Werber - TD Cowen Sarah Schram - William Blair Sam Lee - Mizuho Securities Operator Good afternoon, ladies and gentlemen, and welcome to Alector Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Negative
Zacks Investment Research
2 months ago
Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.49 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK 4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates , including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m.
Neutral
GlobeNewsWire
2 months ago
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
2 months ago
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m.
Neutral
GlobeNewsWire
4 months ago
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration
Charts implemented using Lightweight Charts™